STOCK TITAN

CONMED Corporation - CNMD STOCK NEWS

Welcome to our dedicated page for CONMED Corporation news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on CONMED Corporation stock.

CONMED Corporation (symbol: CNMD) is a global leader in medical technology, specializing in the development and sale of innovative surgical and patient monitoring products. Headquartered in Utica, New York, CONMED employs approximately 3,500 individuals who are dedicated to improving healthcare quality through high-quality product design, production, and marketing.

The company's core business encompasses a diverse range of specialties, including orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. These products are known for their technological advancements, enabling physicians to deliver superior care and achieve enhanced clinical outcomes for their patients.

CONMED operates through two primary reporting units: Orthopedic Surgery and General Surgery. Geographically, the company is U.S.-centric, with the majority of its revenue generated domestically. The EMEA region contributes the second-largest revenue share, followed by APAC and the non-U.S. Americas.

The company's recent achievements include advancements in their surgical products and technology, which continue to set industry standards. Current projects are focused on enhancing product efficiency and expanding their global reach through strategic partnerships and innovations.

CONMED's mission centers around improving healthcare quality. Each employee is committed to customer satisfaction and enhanced patient outcomes, reflecting the company's core values. They strive to exhibit thoughtful leadership, provide meaningful opportunities for employees, and act as a responsible corporate citizen in the communities where they operate.

Recent news highlights include ongoing developments in their product lines and strategic initiatives to bolster market presence. With a strong financial foundation and continuous innovation, CONMED remains a pivotal player in the medical technology sector.

Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) declared a quarterly cash dividend of $0.20 per share. This dividend is payable on July 6, 2021, to shareholders of record as of June 15, 2021. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various specialties, including orthopedics and general surgery. For additional details, visit www.conmed.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
dividends
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) reported first-quarter 2021 financial results, highlighting a sales increase of 8.7% year-over-year to $232.7 million. Domestic revenue rose 4.3%, while international revenue surged 14.3%. Diluted EPS rose 55.0% to $0.31. The company enhanced its 2021 revenue guidance to between $1.0 billion and $1.03 billion, up from $975 million to $1.02 billion. Adjusted diluted EPS guidance is now $3.05 to $3.20, improved from $2.85 to $3.05.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.16%
Tags
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) will report its first-quarter 2021 financial results after market close on April 28, 2021. Management will host a conference call at 4:30 p.m. ET the same day to discuss the results. Investors can participate by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) using passcode 1487002. The call will also be webcast on the company's website, with a replay available one hour post-call. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) has announced its Annual Meeting of Stockholders, to be held virtually on May 19, 2021, at 1:30 p.m. ET. Shareholders of record by March 29, 2021, are eligible to vote. CONMED specializes in medical technology, particularly surgical devices for minimally invasive procedures across various specialties. The company cautions that forward-looking statements may be affected by uncertainties, including the impact of COVID-19 on surgical volumes and supply chains, among other risk factors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) announced participation in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2021, at 11:30 a.m. ET. The session will feature Chair and CEO Curt R. Hartman and CFO Todd W. Garner. Investors can access the live webcast via the Company’s website at www.conmed.com, which will be available for replay post-event. CONMED specializes in minimally invasive surgical devices used across various medical specialties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share, payable on April 5, 2021 to shareholders on record as of March 15, 2021.

CONMED is a medical technology company that provides surgical devices for minimally invasive procedures, serving various specialties including orthopedics and neurosurgery. The announcement reflects the company's ongoing commitment to returning value to shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
dividends
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) announced participation of Curt R. Hartman, Chair of the Board and CEO, alongside Todd W. Garner, CFO, in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference. The event is scheduled for 9:20 a.m. ET on February 25, 2021.

The live webcast will be available in the ‘Investors’ section of their website, and a replay will be accessible post-event. CONMED is a provider of surgical devices for minimally invasive procedures across various specialties, including orthopedics and neurosurgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
conferences
-
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) reported Q4 2020 sales of $252.8 million, down 4.5% year-over-year, with domestic revenue decreasing 0.7% and international revenue falling 9.1%. Diluted EPS rose to $0.81 from $0.49 in Q4 2019, while adjusted EPS decreased from $0.90 to $0.84. For the full year, sales were $862.5 million, a 9.7% decline, and diluted EPS was $0.32 versus $0.97 in 2019. The company expects 2021 revenue between $975 million and $1.02 billion, with adjusted EPS forecasted at $2.85 to $3.05.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
-
Rhea-AI Summary

CONMED Corporation (CNMD) will report its fourth quarter and full year 2020 financial results on January 27, 2021, post-market close. A conference call hosted by management will take place at 4:30 p.m. ET to discuss these results. Participants can join the call by dialing specific numbers provided or via a webcast accessible through the company’s website. A recording of the call will be available for one week following the event. The company specializes in surgical devices for minimally invasive procedures across various medical specialties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
Rhea-AI Summary

CONMED Corporation (NYSE: CNMD) announces that Curt R. Hartman and Todd W. Garner will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2021, at 10:00 a.m. ET. The presentation will be accessible via a live webcast on the Company's website at www.conmed.com, with a replay available post-event. CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties, including orthopedics and neurosurgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
conferences

FAQ

What is the current stock price of CONMED Corporation (CNMD)?

The current stock price of CONMED Corporation (CNMD) is $75.35 as of September 19, 2024.

What is the market cap of CONMED Corporation (CNMD)?

The market cap of CONMED Corporation (CNMD) is approximately 2.3B.

What does CONMED Corporation specialize in?

CONMED Corporation specializes in the development and sale of surgical and patient monitoring products across various medical specialties.

Where is CONMED Corporation headquartered?

CONMED Corporation is headquartered in Utica, New York.

How many employees does CONMED Corporation have?

CONMED Corporation employs approximately 3,500 individuals.

What are the main product specialties of CONMED Corporation?

The main product specialties include orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology.

What are the primary reporting units of CONMED Corporation?

The primary reporting units are Orthopedic Surgery and General Surgery.

In which regions does CONMED Corporation generate most of its revenue?

CONMED Corporation generates most of its revenue in the U.S., followed by the EMEA region, APAC, and the non-U.S. Americas.

What is the mission of CONMED Corporation?

CONMED's mission is to improve healthcare quality by designing, producing, and marketing innovative, high-quality products.

How does CONMED Corporation ensure customer and patient satisfaction?

CONMED focuses on thoughtful leadership, employee opportunities, and responsible community engagement to ensure customer and patient satisfaction.

What recent achievements has CONMED Corporation made?

Recent achievements include advancements in surgical products and technology, enhancing product efficiency and global reach through strategic partnerships.

What is CONMED Corporation's approach to innovation?

CONMED emphasizes continuous innovation by setting industry standards and focusing on product improvements that enhance clinical outcomes.

CONMED Corporation

NYSE:CNMD

CNMD Rankings

CNMD Stock Data

2.34B
30.83M
0.56%
119.87%
11.62%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
LARGO